Agilent Technologies Names Diagnostics and Genomics Group President
News Sep 14, 2012
Holmkvist is currently president and CEO of Dako, a company within DGG. Dako develops and produces cancer diagnostic tools, providing antibodies, reagents, scientific instruments and software to customers in pathology laboratories.
Also encompassed in DGG is Agilent's Genomics Solutions Division.
Holmkvist will continue to report to Bill Sullivan, Agilent president and CEO, who said, "As we move forward, the work being done in our Diagnostics and Genomics Group underscores Agilent's commitment to growth in diagnostics and a leadership position in life sciences. Lars' experience and depth of knowledge in the life sciences arena make him the ideal person to direct our efforts in diagnostics and take advantage of the many opportunities in Agilent's expanding markets."
Holmkvist joined Agilent on June 21, when Dako, a Danish diagnostics company, was acquired by Agilent. He has been president and CEO of Dako since 2009. Before joining Dako, he served as President Europe for Applied Biosystems, where he was later promoted to President International with responsibility for all commercial operations outside the U.S. Before that, Holmkvist was at Medtronic Vascular & Cardiac Surgery, where he was vice president for Europe, the Middle East and Africa.
Holmkvist brings more than 25 years of experience within the medical device and pharmaceutical industries, where he has held several roles in marketing, sales and business management. He has lived and worked internationally for more than 15 years.
A new form of synthetic DNA expands the information density of the genetic code, that likely preserves its capability for supporting life, according to a new study. By expanding the genetic alphabet from four letters to eight, researchers demonstrate the ability to double the information density in DNA.READ MORE
15th International Conference on Surgical Pathology and Cancer Diagnosis
Apr 15 - Apr 16, 2019